Hitachi offers high-field open
Hitachi Medical Systems formally launched its 1.2T vertical field open MR scanner at the RSNA meeting. Oasis, shown as a work-in-progress at last year’s meeting, cleared the FDA in September.
Hitachi Medical Systems formally launched its 1.2T vertical field open MR scanner at the RSNA meeting. Oasis, shown as a work-in-progress at last year's meeting, cleared the FDA in September. Built around a gradient system with 33 mT/m amplitude and 100 T/m/sec slew rate, the scanner features Zenith RF coils. These coils are the culmination of 20 years' experience in the development of vertical field MR, according to Hitachi. Field uniformity is driven by the company's proprietary Higher-Order Active Shim Technology, which is designed to ensure fat saturation over the scanner's large field-of-view. Oasis also features Hitachi's RAPID parallel imaging, TRAQ time-resolved MR angiography, and RADAR patient-motion compensating technology.
Hitachi is also unveiling a new pulse sequence for the cylindrical 1.5T Echelon scanner. The TIGRE sequence supports dynamic abdominal and bilateral breast studies at high temporal and spatial resolution.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
